Nikhil Khushalani, MD, discusses the clinical potential of RP1 plus nivolumab in patients with PD-1–refractory melanoma as well as considerations regarding its use.
Furthering Treatment With Novel Therapies and Multidisciplinary Care in Advanced Melanoma After PD-1 Inhibition
Dr Pavlick discusses the investigation of RP1 plus nivolumab in patients with advanced melanoma who have received prior immune checkpoint inhibition.
Anna C. Pavlick, BSN, MSc, DO, MBA, discusses data for RP1 plus nivolumab and the evolving treatment landscape in advanced melanoma.
Anna C. Pavlick, BSN, MSc, DO, MBA, discusses efficacy data with RP1 plus nivolumab in patients with melanoma who had progressed on PD-1–directed therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5